Preclinical studies have shown that treatment with dendritic cells (DCs) engineered to express the chemokine CCL21 can enhance the infiltration of DCs, CD4+, and CD8+ T cells into the lung tumor microenvironment (TME), thereby effectively reducing tumor burden [26,27]. This evidence concerns the gene CCL21 and neoplasm.